[1] Karkowska-Kuleta J, Rapala-Kozik M, Kozik A. Fungi pathogenic to humans: molecular bases of virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus [J]. Acta Biochimica Polonica,2009,56(2):211-224. [2] Davis NF, Symth LG, Mulcahy E, et al. Ureteric obstruction due to fungus-ball in a chronically immunosuppressed patient[J]. Can Urol Assoc J,2013,7(5):355-358. [3] Yamashita K, Ohara M, Kojima T,et al. Prevalence of drug-resistant opportunistic microorganisms in oral cavity after treatment for oral cancer[J]. J Oral Sci,2013,55(2):145-155. [4] Eddouzi J, Parker JE,Vale-Silva LA,et al.Molecular mechanisms of drug resistance in clinical Candida species isolated from tunisian hospitals[J]. Antimicrob Agents chemother,2013,57(7):3182-3193. [5] Ana B,Herrero M,Carmen Lo'pez,et al. Control of Filament Formation in Candida albicans by Polyamine Levels [J]. Infec Immunity,1999, 67(9):4870-4878. [6] Negredo A, Monteoliva L, Gil C, et al. Cloning, analysis and one-step disruption of the ARG5,6 gene of Candida albicans[J]. Microbiology,1997, 143(2): 297-302. [7] Care RS, Trevethick J, Binley KM, et al. The MET3 promoter: a new tool for Candida albicans molecular genetics[J]. Mol Microbiol,1999,34(4):792-798. [8] 李莹,李德东,王彦,等.白念珠菌IFD6基因高表达促进生物被膜形成[J].第二军医大学学报,2010,31(6):599-603. [9] Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections[J]. Eur J Cancer Care (Engl),2001, 10(1):56-62. [10] Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida albicans yeasts[J]. Curr Drug Targets,2006, 7(4):495-504. [11] Scherer S,Magee PT. Genetics of Candida albicans[J]. Microb Rev, 1990,54(3):226-241. [12] Hernday AD, Noble SM, Mitrovich QM, Johnson AD. Genetics and molecular biology in Candida albicans[J]. Methods Enzymol,2010,470(10): 737-758. |